Cogent Biosciences, Inc. (COGT)
NASDAQ: COGT · Real-Time Price · USD
9.20
+0.12 (1.32%)
Nov 21, 2024, 10:54 AM EST - Market open
Cogent Biosciences Employees
Cogent Biosciences had 164 employees as of December 31, 2023. The number of employees increased by 26 or 18.84% compared to the previous year.
Employees
164
Change (1Y)
26
Growth (1Y)
18.84%
Revenue / Employee
n/a
Profits / Employee
-$1,477,421
Market Cap
1.02B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 164 | 26 | 18.84% |
| Dec 31, 2022 | 138 | 61 | 79.22% |
| Dec 31, 2021 | 77 | 62 | 413.33% |
| Dec 31, 2020 | 15 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Brookdale Senior Living | 36,000 |
| Owens & Minor | 22,200 |
| Phibro Animal Health | 1,940 |
| HealthStream | 1,092 |
| Weave Communications | 844 |
| Zymeworks | 278 |
| Collegium Pharmaceutical | 197 |
| Avadel Pharmaceuticals | 154 |
COGT News
- 5 months ago - Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) - GlobeNewsWire
- 6 months ago - Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer - GlobeNewsWire
- 6 months ago - Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting - GlobeNewsWire
- 7 months ago - Cogent Biosciences Reports First Quarter 2024 Financial Results - GlobeNewsWire
- 8 months ago - Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor - GlobeNewsWire
- 9 months ago - Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 9 months ago - Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis - GlobeNewsWire
- 10 months ago - Cogent Biosciences Announces Oversubscribed $225 Million Private Placement - GlobeNewsWire